Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

• Status: Not yet recruiting
• Trial end date: 2025-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China National Center for Cardiovascular Diseases
• Treatments: Warfarin

Criteria

Inclusion Criteria:

Adult patients undergoing CE+CABG during the study period.

Exclusion Criteria:

1. Patients with high bleeding risk (HAS-BLED ≥ 3);

2. Patients undergoing concomitant aortic valve or mitral valve surgery, or undergoing cardiac surgery for the second time;

3. Emergency surgery;

4. Serum creatinine >130μmol/L, or significant liver dysfunction (elevated ALT and/or AST);

5. History of digestive or urinary tract bleeding, active gastric bleeding caused by gastric ulcer, or postoperative new-onset gastric bleeding;

6. History of hemorrhagic stroke, or platelet dysfunction;

7. Allergic or with contraindication to any of aspirin, clopidogrel or warfarin;

8. Participated in other clinical trial for drug or device within 30 days;

9. Pregnant or planning to be pregnant.